Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Cancer Discov. 2014 Oct;4(10):1214–1229. doi: 10.1158/2159-8290.CD-13-1007

Figure 6. Inhibition of IKK and MEK synergize in vitro.

Figure 6

A. Western blot of 501mel human melanoma cells treated with 1μM AZD6244 (MEKi) and 0.5μM BMS-345541 (IKKi) either alone or in combination for 48hrs for MITF, pIKBα, cleaved caspase-3, pERK and ERK2. B. Drug dose response analysis of 501mel human melanoma cell survival in response to MEKi AZD6244, in combination of either 50ng TNFα or 0.1μM BMS-345541 for 72hrs. C. Drug dose response analysis of WM266-4 melanoma cell survival in response to MEKi PD184352, in combination of either 50ng TNFα or 0.1μM or 0.25μM BMS-345541 for 72hrs. D. BRafV600E-4434 melanoma cells were treated with 0.5μM AZD6244 (MEKi) and 0.1μM BMS-345541 (IKKi) either alone or in combination for 48hrs. E. Summary of drug treatments in the indicated cell lines.